Work

The Duration of Immunotherapy for Mismatch Repair–Deficient Cancers

Year: 2025

Type: article

Abstract: An analysis of published studies suggests that a longer duration of immune checkpoint inhibitor therapy is associated with a higher incidence of complete response among patients with mismatch repair–deficient cancers.

Source: New England Journal of Medicine

DOI: 10.1056/nejmc2409154

Authors: Benoit Rousseau, James R. White, Andrea Cercek, Luis A. Diaz

Institutions: Memorial Sloan Kettering Cancer Center, Resphera Biosciences

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Memorial Sloan-Kettering Cancer Center, Swim Across America, Stand Up To Cancer, National Cancer Institute

Awards: G7410151342, G7912190759, G841809485, Cancer Center Support Grant

OpenAlex ID: W4407732873

FWCI: 11.7

Cites: 4

Cited by: 33

Related to: 10